Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$11.16 - $31.67
Next Earnings Date
May 06 2025
Next Earnings Date
May 06 2025
Latest price
Market Cap | $1.17B |
EV | $1.32B |
Shares Outstanding | 46.28M |
Beta | 0.71 |
Analyst Rating | HOLD |
Analyst Target Price | $36.00 |
P/E 2025E | 8.68x |
P/Revenue 2025E | 1.55x |
Revenue | 9.00% |
EPS | 2.20% |
Operating Cash Flow | 14.60% |
Free Cash Flow | 30.80% |
Revenue | 10.40% |
EPS | 12.50% |
Operating Cash Flow | 10.00% |
Free Cash Flow | 1.60% |
Gross Margin 2025E | 77.37% |
Net Profit Margin 2025E | 6.99% |
ROE 2025E | 10.67% |
ROCE 2024 | -12.08% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Pacira BioSciences, Inc.
PCRX
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Lee, Frank
Employees
789
Website
www.pacira.comIPO Date
2011-02-03
Headquarters
5401 West Kennedy Boulevard, Suite 890, Tampa, Florida, 33609, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved